The world of nephrology is buzzing with excitement as we reflect on the groundbreaking advancements presented at the American Society of Nephrology's Kidney Week 2025. This event, held in Houston, Texas, showcased the incredible progress and potential for redefining kidney care. With FDA approvals for IgA nephropathy and C3 glomerulopathy, and a growing body of evidence supporting immune-targeted strategies, the field is on the cusp of a new era.
Kidney Week 2025 highlighted the momentum across various disciplines, from glomerular diseases to transplant immunology. It's an exciting time as the focus shifts from supportive care to targeted interventions that can significantly impact long-term kidney health.
Let's dive into eight key trial updates from the meeting, which offer a glimpse into the future of nephrology.
Atacicept's Potential in IgA Nephropathy: The ORIGIN 3 trial revealed atacicept, a dual BAFF/APRIL inhibitor, reduced proteinuria by an impressive 45.7% after 36 weeks. This treatment showed strong biological and clinical effects, including a significant drop in Gd-IgA1 levels and resolution of hematuria. Safety data indicated a higher rate of injection-site reactions but fewer serious adverse events compared to the placebo.
Finerenone's Benefits for Type 1 Diabetes and CKD: Finerenone demonstrated a relative reduction of 25% in UACR over six months compared to a placebo in adults with type 1 diabetes and chronic kidney disease. This aligns with ADA thresholds, suggesting a slower progression of kidney disease. The safety profile was consistent with previous finerenone programs, with no new safety concerns identified.
Fish Oil's Impact on Cardiovascular Events: The PISCES trial showed that 4 grams of n−3 polyunsaturated fatty acids (n-3 PUFA) daily significantly reduced the rate of serious cardiovascular events in adults on maintenance hemodialysis. The benefits were consistent across various cardiovascular outcomes, and no major safety concerns emerged in the study cohort.
Setanaxib's Promise in Alport Syndrome: In a phase 2a trial, setanaxib proved safe and well-tolerated in patients with Alport syndrome. Despite already optimized RAASi and SGLT2 inhibitor therapy, setanaxib achieved a mean reduction in proteinuria, with a notable sustained effect even after treatment discontinuation.
MIL62's Success in Membranous Nephropathy: MIL62, a glycoengineered anti-CD20 antibody, achieved higher complete remission rates compared to cyclosporine A in a phase 3 trial for primary membranous nephropathy. MIL62 also demonstrated faster and deeper disease control, with significant improvements in eGFR and quality of life measures.
Povetacicept's Validation in IgAN and pMN: Povetacicept, another dual BAFF/APRIL inhibitor, showed substantial proteinuria reductions in both IgAN and primary MN. The treatment led to early, deep, and sustained reductions in pathogenic biomarkers, suggesting a potential disease-modifying effect. Safety data indicated generally good tolerance, with monitored IgG reductions but no serious infections.
Tegoprubart's Safer Approach to Kidney Transplant Rejection: The BESTOW trial compared tegoprubart to tacrolimus in kidney transplant recipients. Tegoprubart achieved comparable eGFR to tacrolimus at 12 months, with a more favorable safety profile, including lower rates of new-onset diabetes, tremor, and delayed graft function.
Telitacicept's Primary Endpoint Achievement in IgA Nephropathy: In a phase 3 study, telitacicept, a BLyS/APRIL-targeting fusion protein, reduced 24-hour proteinuria by 58.9% compared to 8.8% with placebo. Telitacicept also achieved clinically meaningful proteinuria thresholds more frequently, with stable kidney function and a lower risk of eGFR decline.
These trial updates highlight the incredible progress and potential for improving kidney health. As we continue to explore these advancements, it's an exciting time for the nephrology community and those affected by kidney diseases.
What are your thoughts on these groundbreaking developments? Share your insights and join the discussion in the comments below!
